<!DOCTYPE html lang="EN">
<html>
<head>
	
	<meta content="text/html; charset=UTF-8" http-equiv="Content-Type" />
	<title>Hormonal Replacement in Hypopituitarism in Adults_2017</title>
	<meta content="width=device-width; initial-scale=1.0; maximum-scale=1.5; user-scalable=1;" name="viewport" />
	<link charset="UTF-8" href="HighLight.css" rel="STYLESHEET" type="text/css" />
	<script src="jquery-3.1.0.min.js"></script>
	<script type = "text/javascript" src = "HighlightSearch.js"></script>
	 <link rel="stylesheet" type="text/css" href="calci_std.css">
	 <link rel="stylesheet" type="text/css" href="ENAS5329.css">
</head>
<body onload="_geturl1();">


<table class="table">
	<colgroup>
		<col width="40%" />
		<col width="60%" />
	</colgroup>
	<tbody>
		<tr>
			<th class="table-header1" colspan="2">
			<p class="table-title1">Table 9: Rec&shy;om&shy;mend&shy;ed doses of an&shy;tithrom&shy;bot&shy;ic agents in the acute care of pa&shy;tients with chron&shy;ic kid&shy;ney</p>
			</th>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">As&shy;pirin</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 150&ndash;300 mg oral&shy;ly fol&shy;lowed by a main&shy;te&shy;nance dose of 75&ndash;100 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Clopi&shy;do&shy;grel</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 300&ndash;600 mg oral&shy;ly fol&shy;lowed by 75 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No in&shy;for&shy;ma&shy;tion avail&shy;able</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Tica&shy;grelor</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 180 mg oral&shy;ly fol&shy;lowed 90 mg twice a day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Pra&shy;sug&shy;rel</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Load&shy;ing dose of 60 mg oral&shy;ly fol&shy;lowed by 10 mg/&zwj;day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Enoxa&shy;parin</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">1 mg/kg <span class="italic">s.c.</span> twice a day,</p>

			<p class="table-text">0.75 mg/kg <span class="italic">s.c.</span> twice daily in pa&shy;tients &ge;75 years old.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">1 mg/kg <span class="italic">s.c.</span> once a day</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">UFH</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text"><span class="italic">Be&shy;fore coro&shy;nary an&shy;giog&shy;ra&shy;phy:</span></p>

			<p class="indent">Bolus 60&ndash;70 IU/kg <span class="italic">i.v.</span> (max&shy;i&shy;mum 5000 IU) and in&shy;fu&shy;sion (12&ndash;15 IU/&zwj;kg/&zwj;hour, max&shy;i&shy;mum 1000 IU/&zwj;hour), tar&shy;get aPTT 1.5&ndash;2.5 x con&shy;trol.</p>

			<p class="table-text"><span class="italic">Dur&shy;ing PCI:</span></p>

			<p class="indent">70-100 IU/kg <span class="italic">i.v.</span> (50-70 IU/kg if con&shy;comi&shy;tant with GP IIb/&zwj;IIIa in&shy;hibitors).</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">No dose ad&shy;just&shy;ment</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Fon&shy;da&shy;parin&shy;ux</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">2.5 mg <span class="italic">s.c.</span> once a day.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>

			<p class="table-text">if eGFR &lt;20 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span> or dial&shy;y&shy;sis</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Bi&shy;valirudin</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Bolus 0.75 mg/kg <span class="italic">i.v.</span>, in&shy;fu&shy;sion 1.75 mg/&zwj;kg/&zwj;hour.</p>

			<p class="table-text"><span class="italic">If eGFR &ge;30 and &le;60 mL/&zwj;min/&zwj;1.73m<span class="text-sup">2</span> re&shy;duce in&shy;fu&shy;sion dose to 1.4 mg/&zwj;kg/&zwj;hour.</span></p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Ab&shy;cix&shy;imab</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Bolus of 0.25 mg/kg <span class="italic">i.v.</span> fol&shy;lowed by 0.125 μg/&zwj;kg/&zwj;min in&shy;fu&shy;sion (max&shy;i&shy;mum 10 μg/min).</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Care&shy;ful con&shy;sid&shy;er&shy;a&shy;tion of bleed&shy;ing risk</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Care&shy;ful con&shy;sid&shy;er&shy;a&shy;tion of bleed&shy;ing risk</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Ep&shy;ti&shy;fi&shy;batide</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Bo&shy;lus<span class="text-sup">a</span> of 180 μg/kg <span class="italic">i.v.</span> fol&shy;lowed by an in&shy;fu&shy;sion of 2.0 μg/&zwj;kg/&zwj;min for up to 18 hours.</p>

			<p class="table-text">If eGFR &lt;50 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span> re&shy;duce in&shy;fu&shy;sion dose to 1.0 μg/&zwj;kg/&zwj;min.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
		<tr>
			<th class="table-header2" colspan="2">
			<p class="table-title2">Tirofiban</p>
			</th>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Nor&shy;mal renal func&shy;tion and stage 1&ndash;3 CKD</p>

			<p class="table-text">(eGFR &ge;30 mL/min/1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Bolus 25 μg/kg <span class="italic">i.v.</span> fol&shy;lowed by 0.15 μg/&zwj;kg/&zwj;min.</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 4 CKD</p>

			<p class="table-text">(eGFR 15 to &lt;30 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Re&shy;duce in&shy;fu&shy;sion rate to 50%</p>
			</td>
		</tr>
		<tr>
			<td class="col-purple">
			<p class="table-text">Stage 5 CKD</p>

			<p class="table-text">(eGFR &lt;15 mL/&zwj;min/&zwj;1.73 m<span class="text-sup">2</span>)</p>
			</td>
			<td>
			<p class="table-text">Not rec&shy;om&shy;mend&shy;ed</p>
			</td>
		</tr>
	</tbody>
</table>


     <br>
	 <div style="float:right; width:70px; paddin:0px 0px 3px 0px;   ">
                <button id="pdf_button"  class="flip-pdf-button"  >
                    <a href="flipView"> <img src="algo.png" class="pdf-image "></img></a>
                </button>
        </div>
		<br/><br/>
		 <div class="static-reference-box">
  <p class="text_left">aPTT = activated partial thromboplastin time; CKD = chronic kidney disease; eGFR = estimated
glomerular filtration rate; GP = glycoprotein; IU = international units; <i>i.v.</i> = intravenous; PCI = percutaneous coronary intervention; <i>s.c.</i> = subcutaneous; UFH = unfractionated heparin.
                            </p>
                        </div>
     <div class="static-reference-box">
  <p class="text_left">*Normal renal function and stage 1–3 CKD (eGFR &ge;30 mL/min/1.73 m<sup>2</sup>)<br/>**Stage 4 CKD (eGFR 15 to <30 mL/min/1.73 m<sup>2</sup>)<br/>***Stage 5 CKD (eGFR <15 mL/min/1.73 m<sup>2</sup>)<br/><sup>a</sup>Double bolus if administered during primary PCI.
                            </p>
                        </div>
</body>
</html>
